Moderately good evidence favours omega-3 fatty acids, notably eicosapentaenoic acid (EPA), for reducing cardiovascular mortality and outcomes, concludes Professor Mike Miller, with a recent meta analysis supporting EPA use in current treatment of residual cardiovascular risk and encouraging further exploration of its cardiovascular effects in different clinical settings.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
